



## **Table 3. Commonly Used Abbreviations**

| Abbreviation | Definition and Notes                       |  |  |
|--------------|--|--|--|
| ACA          | Patient Protection and Affordable Care Act |  |  |
| AFP          | alpha-fetoprotein                          |  |  |
| ALT          | alanine aminotransferase                   |  |  |
| AMP          | average manufacturer price                 |  |  |
| Anti-HCV     | HCV antibody                               |  |  |
| APRI         | AST-to-platelet ratio index                |  |  |
| AST          | aspartate aminotransferase                 |  |  |
| AUC          | area under the curve                       |  |  |
| AWP          | average wholesale price <sup>a</sup>       |  |  |
| BOC          | boceprevir                                 |  |  |
| CBC          | complete blood count                       |  |  |
| CDC          | Centers for Disease Control and Prevention |  |  |
| CEA          | cost-effectiveness analysis                |  |  |
| СТР          | Child-Turcotte-Pugh (see below)            |  |  |
| СҮР          | cytochrome P450                            |  |  |
| DAA          | direct-acting antiviral                    |  |  |
| eGFR         | estimated glomerular filtration rate       |  |  |
| ESRD         | end-stage renal disease                    |  |  |
| FDA          | US Food and Drug Administration            |  |  |
| GFR          | glomerular filtration rate                 |  |  |
| HBsAg        | hepatitis B virus surface antigen          |  |  |
| HBV          | hepatitis B virus                          |  |  |
|              |  |  |  |





## **Table 3. Commonly Used Abbreviations**

Published on HCV Guidance (https://www.hcvguidelines.org)

| Abbreviation | Definition and Notes  |  |  |
|--------------|---|--|--|
| HCC          | hepatocellular carcinoma  |  |  |
| HCV          | hepatitis C virus Hepatitis C virus and HCV refer to the virus. Hepatitis C and HCV infection or HCV disease refer to the disease entity. |  |  |
| ICER         | incremental cost-effectiveness ratio  |  |  |
| IDU          | injection drug use or user  |  |  |
| INR          | international normalized ratio  |  |  |
| MELD         | model for end-stage liver disease   |  |  |
| MSM          | men who have sex with men   |  |  |
| NASH         | nonalcoholic steatohepatitis  |  |  |
| NAT          | nucleic acid testing  |  |  |
| NIH          | National Institutes of Health   |  |  |
| NS3          | HCV nonstructural protein 3   |  |  |
| NS5A         | HCV nonstructural protein 5A  |  |  |
| OATP         | organic anion-transporting polypeptide  |  |  |
| РВМ          | pharmacy benefit manager  |  |  |
| PCR          | polymerase chain reaction   |  |  |
| P-gp         | P-glycoprotein  |  |  |
| PreP         | preexposure prophylaxis   |  |  |
| PWID         | people who inject drugs   |  |  |
| QALY         | quality-adjusted life-year  |  |  |
| RAS          | resistance-associated substitution  |  |  |
| RBC          | red blood cell(s)   |  |  |
| RBV          | ribavirin   |  |  |
| RGT          | response-guided therapy   |  |  |
| sAg          | surface antigen   |  |  |
| SMV          | simeprevir  |  |  |
| SOF          | sofosbuvir  |  |  |
|              |   |  |  |





## **Table 3. Commonly Used Abbreviations**

Published on HCV Guidance (https://www.hcvguidelines.org)

| Abbreviation   | Definition and Notes   |  |  |
|--|--|--|--|
| SVR12 (or 24 or 48, etc)   | sustained virologic response at 12 weeks (or at 24 weeks, or at 48 weeks, etc) |  |  |
| TSH  | thyroid-stimulating hormone  |  |  |
| TVR  | telaprevir   |  |  |
| ULN  | upper limit of normal  |  |  |
| USPSTF   | US Preventive Services Task Force  |  |  |
| WAC  | wholesale acquisition cost <sup>b</sup>  |  |  |
| <sup>a</sup> "List price" for wholesale pharmacies to purchase drugs |  |  |  |

<sup>&</sup>lt;sup>b</sup> Typically, approximately 17% off of AWP

| Child-Turcotte-Pugh (CTP) Classification of the Severity of Cirrhosis |         |   |                              |  |  |
|---|---------|---|------------------------------|--|--|
|   | CLASS A | CLASS B                                   | CLASS C                      |  |  |
| Total Points  | 5-6     | 7-9                                       | 10-15                        |  |  |
| Factor  | 1 Point | 2 Points                                  | 3 Points                     |  |  |
| Total bilirubin (µmol/L)  | <34     | 34-50                                     | >50                          |  |  |
| Serum albumin (g/L)   | >35     | 28-35                                     | <28                          |  |  |
| Prothrombin time / international normalized ratio                     | <1.7    | 1.71-2.3                                  | >2.3                         |  |  |
| Ascites   | None    | Mild                                      | Moderate to Severe           |  |  |
| Hepatic encephalopathy  | None    | Grade I-II (or supressed with medication) | Grade III-IV (or refractory) |  |  |

Last update: November 6, 2019